| |
| | References |
 | | Petrylak DP, Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG, Figgitt DP, Wiseman LR: Docetaxel (Taxotere) in hormone-refractory prostate cancer. |
 | | Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR, Kris MG, Figgitt DP, Wiseman LR: Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. |
 | | Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. |
| www.medscape.com /content/2004/00/48/74/487450/487450_ref.html (1192 words) |
|